These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 23466576)

  • 21. Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.
    Belgioia L; Vagge S; Agnese D; Garelli S; Murialdo R; Fornarini G; Chiara S; Gallo F; Bacigalupo A; Corvò R
    World J Gastroenterol; 2015 Oct; 21(37):10688-96. PubMed ID: 26457030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma.
    Clavel S; Nguyen DH; Fortin B; Després P; Khaouam N; Donath D; Soulières D; Guertin L; Nguyen-Tan PF
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):582-9. PubMed ID: 21277695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
    Chakravarty T; Crane CH; Ajani JA; Mansfield PF; Briere TM; Beddar AS; Mok H; Reed VK; Krishnan S; Delclos ME; Das P
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):581-6. PubMed ID: 22137021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
    Ferrigno R; Nakamura RA; Dos Santos Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV; Filho WJ; Lopes A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1136-42. PubMed ID: 15752894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
    Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
    Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
    Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy.
    Schoenfeld JD; Sher DJ; Norris CM; Haddad RI; Posner MR; Balboni TA; Tishler RB
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):308-14. PubMed ID: 21075557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IMRT with simultaneous integrated boost and concurrent chemotherapy for nasopharyngeal cancer: plan evaluation and treatment outcome.
    Kim JW; Cho JH; Keum KC; Kim JH; Kim GE; Lee JY; Kim SK; Lee CG
    Jpn J Clin Oncol; 2012 Dec; 42(12):1152-60. PubMed ID: 23077243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
    Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
    Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Definitive radiotherapy for squamous cell carcinoma of the anal canal.
    Rabbani AN; Zlotecki RA; Kirwan J; George TJ; Morris CG; Rout WR; Mendenhall WM
    Am J Clin Oncol; 2010 Feb; 33(1):47-51. PubMed ID: 19704368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
    Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
    Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer.
    Joseph K; Nijjar Y; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Ghosh S; Syme A; Nijjar T; Mulder K; Doll C; Wong C; Field C
    Radiother Oncol; 2015 Nov; 117(2):234-9. PubMed ID: 26306677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
    Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
    Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
    Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
    DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
    Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients.
    De Bari B; Lestrade L; Franzetti-Pellanda A; Jumeau R; Biggiogero M; Kountouri M; Matzinger O; Miralbell R; Bourhis J; Ozsahin M; Zilli T
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):781-789. PubMed ID: 29441419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
    Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
    Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
    Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma.
    Gordeyev SS; Rasulov AO; Gorbounova VA; Tkachev SI; Glebovskaya VV; Fedyanin MY; Besova NS; Surayeva YE
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):623-629. PubMed ID: 28766008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
    Chen YW; Yen SH; Chen SY; Huang PI; Shiau CY; Liu YM; Lin JK; Wang LW
    J Surg Oncol; 2007 Oct; 96(5):374-80. PubMed ID: 17492635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.